USA Ke Keʻena Ulalani, Kanakā Lahui Nā'Ileʻawa, Nā Hana Hana'Aiwi Pākehā

Powderane Powderane

Rating: SKU: 13647-35-3. Māhele:

ʻO AASraw me ka synthesis a me ka hiki ke hoʻomohala mai ka gram i ka ʻōnaehana laulima o Trilostane Powder (13647-35-3), ma lalo o ke kākala CGMP a me ka ʻōnaehana hoʻokele kūpono.

Product Description

Trilostane Powder (13647-35-3) wikiō


ʻO Trilostane Powder (13647-35-3) Ske kūkala:

Hoʻolālā kūlohelohe: Product Name: Trilostane
Kānāwai No.: 13647-35-3
Ka Lā Molecular: C20H27NO3
Molecular Weight: 329.43
Kūlana: I loko
Puke: Kino, pouli a ma 0 - 4 C no kekahi mau liʻiliʻi (mau lā i nā hebedoma) aiʻole -20 C no ka wā lōʻihi (mau mahina a hiki i nā makahiki).
Nā Palapala Kūlana (COA & HPLC etc.): Available

ʻO Trilostane Powder (13647-35-3) Dinoa:

ʻO ka pauka Trilostane kahi mea hoʻomehana i ka dehydrogenase 3β-hydroxysteroid i hoʻohanaʻia i ka mālamaʻana i ka maʻi Cush a me ka hyperaldosteronism mua. ʻO kēia mau pilikia nā ka hapanui o nā hua corticosteroid i hua ʻia i loko o ke kino. He mea nui ia na Corticosteroids no ke kino e hoʻohana i ka hoʻohana ʻana i nā palaka, ke ake a me nā polokalamu a me nā pane maʻamau i ke kaumaha. Pono lākou no ka hoʻoponopono ʻana o ka paʻakai a me ka wai o ka wai i loko o ke kino. Kōkua ʻo Trilostane pale i ka hana ʻana o nā corticosteroids, e kāohi ana i nā hōʻailona pili i kēia mau maʻi.

Hiki ke loaʻa ka pauma Trilostane i ka mālama ʻana i ka maʻi umauma o ka mea i hoʻomaha i loko o nā wahine i hele i ka menopause.

Nui mea i apono ʻia ma 2008 no ka mālama ʻana i ka maʻi Cush (hyperandrenocorticism) i nā ʻīlio. ʻO ia nō hoʻi ka lāʻau lapaʻau mua i ʻae ʻia e mālama i ka maʻi o ka pituitary- a me ke kākoʻo ʻana o adrenal-Cush i loko o nā ʻīlio. Hana ʻia kēia lāʻau lapaʻau e ka hoʻokō ʻana i ka hana o cortisol i nā kūmole adrenal.

Reference:

  • 1: Midence JN, Drobatz KJ, Hess RS. ʻO nā ʻōpū Cortisol i nā ʻīlio i hoʻoponopono maikaʻi ʻia me Hyperadrenocorticism i mālama ʻia me Trilostane. J Vet Intern Med. 2015 Nov; 29 (6): 1529-33. doi: 10.1111 / jvim.13615. Epub 2015 Sep 16. PubMed PMID: 26374943.
  • 2: Fracassi F, Corradini S, Floriano D, Boari A, Aste G, Pietra M, Bergamini PF, Dondi F. Prognostic mau ola no ke ola ʻana i nā ʻīlio me ka hypercortisolism hilinaʻi-lapaʻau i mālama ʻia me trilostane. Vet Rec. 2015 Jan 10; 176 (2): 49. doi: 10.1136 / vr.102546. Epub 2014 Aug 28. PubMed PMID: 25170036.
  • 3: Bonadio CM, Feldman EC, Cohen TA, Kass PH. ʻO ka hoʻohālikelike o ka hoʻāʻo ʻana e hoʻoulu i ka hana adrenocorticotropic i hoʻomaka i 2 mau kū i 4 mau hola ma hope o ka hoʻokele trilostane i nā ʻīlio me ka hoʻoulu ʻia ʻana o ka hyperadrenocorticism. J Vet Intern Med. 2014 Jul-ʻAukake; 28 (4): 1239-43. doi: 10.1111 / jvim.12357. Epub 2014 May 26. PubMed PMID: 24863172.

NA HALO A E HOOLAHA:

E kūʻai ʻia ana kēia ʻano mea no ka noiʻi noiʻi wale nō. Wahi a ke kūʻai aku. ʻAʻole no ka loiloi kanaka, ʻaʻole lāʻau lapaʻau, manu hoʻāno, a i ʻole e kōkua ʻia nā mea hale.


COA

HNMR

Nāʻike & nā hua'ōlelo huahana